3,459 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 3,459 shares of the medical equipment provider’s stock, valued at approximately $249,000.

Other institutional investors also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Hologic by 2.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 364,776 shares of the medical equipment provider’s stock valued at $26,297,000 after purchasing an additional 10,049 shares during the period. PNC Financial Services Group Inc. grew its holdings in Hologic by 5.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 39,014 shares of the medical equipment provider’s stock valued at $2,813,000 after buying an additional 1,853 shares during the period. Camden National Bank acquired a new position in shares of Hologic during the 4th quarter valued at about $241,000. E Fund Management Co. Ltd. increased its stake in shares of Hologic by 96.2% during the 4th quarter. E Fund Management Co. Ltd. now owns 5,018 shares of the medical equipment provider’s stock valued at $362,000 after acquiring an additional 2,460 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Hologic in the fourth quarter worth approximately $27,007,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Price Performance

HOLX opened at $60.71 on Friday. Hologic, Inc. has a twelve month low of $60.33 and a twelve month high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a market cap of $13.62 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 2.14 and a beta of 0.97. The company has a fifty day simple moving average of $67.18 and a 200 day simple moving average of $74.71.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target on the stock. Wolfe Research began coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. Raymond James reissued an “outperform” rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Morgan Stanley dropped their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Citigroup reduced their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.